Key result
MAPK15 drives AF pathogenesis via Mcub palmitoylation-induced mitochondrial calcium overload, reversible by palmitoylation inhibition.
Why the study?
The mechanisms driving atrial cardiomyocyte senescence in AF remain elusive, and although MAPK15 regulates epithelial cell senescence, its role in the heart and in AF was unclear.
Does MAPK15 induce atrial cardiomyocyte senescence and atrial fibrillation via palmitoylating Mcub at the C91 residue in preclinical models and human atrial appendage tissues?
Does MAPK15 induce atrial cardiomyocyte senescence and atrial fibrillation via palmitoylating Mcub at the C91 residue in preclinical models and human atrial appendage tissues?
Identifies MAPK15 as a novel regulator that promotes atrial cardiomyocyte senescence and atrial fibrillation via mitochondrial calcium overload through palmitoylation of Mcub at C91, highlighting a potential therapeutic target for age-related AF.
Answers are grounded in this paper and cite their sources.
May identify MAPK15 as an AF target in models; leaves open clinical translation of palmitoylation inhibition.
Aims The prevalence of atrial fibrillation (AF), particularly age-related AF, is increasing rapidly with global aging. Cellular senescence is a key contributing factor to AF, yet the underlying mechanisms driving atrial cardiomyocyte senescence remain elusive. Although MAPK15 has recently been implicated in regulating epithelial cell senescence, its potential role in the heart remains unclear. Therefore, this study aims to investigate the role of MAPK15 in atrial cardiomyocyte senescence and AF, and to elucidate the underlying mechanisms. Methods and Results We investigated the role and underlying mechanisms of MAPK15 in atrial cardiomyocyte senescence and AF by cardiac-specific overexpression or knockdown of MAPK15, as well as treatment with small-molecule inhibitors. A combination of transcriptomic and metabolomic profiling, co-immunoprecipitation with mass spectrometry, site-directed mutagenesis, patch-clamp recording, optical mapping and intracardiac electrophysiology was employed both in vitro and in vivo. Findings were further validated using human atrial appendage specimens. Results showed that MAPK15 was closely associated with atrial cardiomyocyte senescence and AF. Overexpression of MAPK15 aggravated senescence and promoted AF. Mechanistically, MAPK15 induced palmitoylation of mitochondrial calcium uniporter dominant negative subunit b (Mcub) at C91, causing its dissociation from the mitochondrial Mcu complex and translocation to the cytoplasm. This impaired inhibition of mitochondrial calcium uptake, leading to calcium overload, ROS overproduction, and cellular senescence. C91S mutation or palmitoylation inhibition (2-BP) reversed these effects. Subsequently, senescent cardiomyocytes showed increased triggered activity, fibrosis, and altered connexin43 distribution, facilitating AF onset. And serological analysis suggested that IL-17a may act as an upstream regulator of MAPK15. Conclusion Our findings identify MAPK15 as a novel regulator of atrial cardiomyocyte senescence and AF. MAPK15 promotes mitochondrial calcium overload through palmitoylation of Mcub at C91, highlighting a new mechanistic axis linking mitochondrial dysfunction, cellular senescence, and arrhythmogenesis. Translational Perspective Age-related atrial fibrillation is highly prevalent and frequently associated with adverse cardio- and cerebrovascular events, constituting a significant global public health burden. In this study, we demonstrated at both in vivo and in vitro levels that the MAPK15-Mcub axis promotes atrial cardiomyocyte senescence and senescence-associated AF, which was further validated in atrial appendage tissues from clinical patients, enhancing the clinical translational relevance of our findings. Moreover, we identified circulating IL-17a as a potential upstream activator associated with MAPK15 signaling, suggesting its potential utility in preclinical screening and as an insightful clue for future immunomodulatory strategies. The development of small-molecule agents specially targeting MAPK15 or Mcub in cardiomyocytes may represent a novel therapeutic strategy for treating atrial myocyte senescence and AF.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2026) studied Atrial fibrillation and atrial cardiomyocyte senescence. MAPK15 overexpression, knockdown, C91S mutation, or palmitoylation inhibition (2-BP) vs. Control / wild-type was evaluated on Atrial cardiomyocyte senescence, mitochondrial calcium overload, and atrial fibrillation onset. MAPK15 induced Mcub palmitoylation at the C91 residue to cause mitochondrial calcium overload, cardiomyocyte senescence, and atrial fibrillation, which was reversed by C91S mutation or 2-BP.
Synapse has enriched 10 related papers. Consider them for comparative context: